Trial Testing Durvalumab Combinations in Stage III Non-Small Cell Lung Cancer
Researchers are comparing durvalumab in combination with oleclumab, monalizumab, or placebo in patients with non-small cell lung cancer.
All articles by Cancer Therapy Advisor Staff
Investigation of Atezolizumab Plus Radiotherapy in Small-Cell Lung Cancer
Researchers are comparing atezolizumab plus radiotherapy with atezolizumab alone in patients with small-cell lung cancer.
Adagrasib vs Docetaxel for KRAS G12C-Mutant Non-Small Cell Lung Cancer
Researchers are comparing adagrasib with docetaxel in non-small cell lung cancer.
Stereotactic Radiosurgery in SCLC With Brain Metastasis
Researchers are comparing stereotactic radiosurgery with hippocampal-avoidant whole-brain radiotherapy plus memantine in patients with brain metastases from SCLC.
Trial Testing Lonca-R in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This phase 3 trial is designed to compare loncastuximab tesirine plus rituximab with standard immunochemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma.
Dociparstat Plus Standard Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia
This phase 3 trial is designed to test dociparstat sodium in combination with standard chemotherapy in newly diagnosed acute myeloid leukemia.
Nivolumab Plus Chemoimmunotherapy for Primary Mediastinal B-Cell Lymphoma
This phase 3 trial is designed to test nivolumab in combination with chemoimmunotherapy in newly diagnosed primary mediastinal B-cell lymphoma.
Venetoclax-Obinutuzumab vs Rituximab Regimens in Fit CLL Patients
This phase 3 study is designed to compare venetoclax plus obinutuzumab with 1 of 2 rituximab-based regimens in previously untreated CLL.
Trial Evaluating Entospletinib Plus Chemo in NPM1-Mutated Acute Myeloid Leukemia
The primary endpoint is MRD-negative complete response rate.
Researchers Seeking Optimal Dose of Idelalisib for Follicular Lymphoma Patients With No Other Options
The primary outcome measures are overall response rate and the incidence of grade 4 or higher treatment-emergent adverse events.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...